Characterization of a DRD2 Variant that is Associated With a Movement Disorder
与运动障碍相关的 DRD2 变体的特征
基本信息
- 批准号:10029640
- 负责人:
- 金额:$ 34.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimal ModelArrestinsBehaviorBindingBiologicalBrainCalmodulinCell LineCell surfaceCellsCharacteristicsChoreaClinicalCrystallizationCyclic AMPDRD2 geneDataDiseaseDopamineDopamine D2 ReceptorDopamine ReceptorDyskinetic syndromeDystoniaElectrophysiology (science)EmbryoEvaluationExhibitsExonsFamilyFunctional disorderG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenerationsGenesGeneticGenetic PolymorphismGoalsGovernmentHumanHuntington geneImpairmentInvestigationKidneyKineticsKnock-in MouseLaboratoriesLinkLipid BilayersMental disordersMidbrain structureModelingMotorMovement DisordersMusMutateNeostriatumNeurologic DysfunctionsNeurologic SymptomsNeuronsParkinson DiseasePathogenicityPersonsPhenotypePropertyRIPK1 geneReceptor SignalingResearchSchizophreniaSignal TransductionSingle Nucleotide PolymorphismSliceStructureSubstance abuse problemSystemTestingTherapeuticVariantWorkdesensitizationdopamine systemdopaminergic neurongenetic pedigreegenetic variantin vivomembermotor impairmentmouse modelmutantnervous system disordernovelprotein activationprotein expressionreceptorreceptor bindingreceptor expressionreceptor functionrecruitsocietal coststherapeutic target
项目摘要
Project Summary
Dopamine receptors are the primary therapeutic targets for a variety of neurological and psychiatric disorders,
including schizophrenia, Parkinson's disease, and many other movement disorders. The five subtypes of
dopamine receptors (D1-D5) are members of the superfamily of G protein-coupled receptors. This proposal is
focused on the D2 receptor and, in particular, on the functional consequences of a novel DRD2 allelic variant
that is linked to a movement disorder in at least one pedigree. The two Aims will test the hypotheses that the
putatively pathogenic variant will exhibit altered signaling and cell surface expression compared to the
reference D2 receptor when expressed in a neuronal cell line (Aim 1) or in dopamine neurons in mouse brain
(Aim 2a), and that mice expressing the novel variant will exhibit motor impairments consistent with the human
phenotype (Aim 2b). In Aim 1 we will determine if the impaired recruitment of arrestin and enhanced activation
of G proteins observed when expressed in human embryonic kidney 293 cells is also characteristic of the novel
variant when expressed in a neuronal cell line. In Aim 2 we will create a knock-in mouse model of homozygous
and heterozygous expression of the putatively pathogenic variant. We will evaluate the functional properties of
the novel variant in midbrain dopamine neurons using slice electrophysiology, and conduct analyses of
behaviors that are thought to model the human clinical condition. In addition, D2 receptor expression will be
quantified in midbrain and neostriatum of the knock-in mouse. The aims proposed here will quantify the effect
of this novel polymorphism on the function and expression of the D2 receptor in neuronal cells and in mouse
brain and should provide a biological explanation for manifestation of neurological dysfunction in humans with
this variant.
项目摘要
多巴胺受体是多种神经和精神疾病的主要治疗靶点,
包括精神分裂症、帕金森氏症和许多其他运动障碍。五种亚型
多巴胺受体(D1-D5)是G蛋白偶联受体超家族的成员。这项建议是
集中在D2受体,特别是一种新的DRD 2等位基因变体的功能后果
与至少一个家系中的运动障碍有关。这两个目标将测试假设,
脓毒症致病性变体将表现出改变的信号传导和细胞表面表达,
当在小鼠脑中的神经元细胞系(Aim 1)或多巴胺神经元中表达时,
(Aim 2a),并且表达新变体的小鼠将表现出与人类一致的运动障碍。
表型(Aim 2b)。在目标1中,我们将确定抑制蛋白的募集受损和激活增强是否与抑制蛋白的表达有关。
当在人胚肾293细胞中表达时观察到的G蛋白的表达也是新的特征。
当在神经元细胞系中表达时,其是变体。在目标2中,我们将建立一个敲入小鼠模型,
以及脓疱病致病性变体的杂合表达。我们将评估的功能特性
中脑多巴胺神经元的新变异,并进行分析,
被认为是模拟人类临床状况的行为。此外,D2受体表达将是
在敲入小鼠的中脑和新纹状体中定量。这里提出的目标将量化效果
这种新的多态性对神经元细胞和小鼠中D2受体的功能和表达的影响
大脑,并应提供一个生物学解释的表现,神经功能障碍的人类与
这个变种。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reply to: "Childhood Onset Chorea Caused by a Recurrent De Novo DRD2 Variant".
回复:“由复发性新发 DRD2 变异引起的儿童期舞蹈病”。
- DOI:10.1002/mds.28635
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:vanderWeijden,MarlousCM;Rodriguez-Contreras,Dayana;Neve,KimA;Verbeek,DinekeS;Tijssen,MarinaAJ
- 通讯作者:Tijssen,MarinaAJ
A Gain-of-Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype.
- DOI:10.1002/mds.28385
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:van der Weijden MCM;Rodriguez-Contreras D;Delnooz CCS;Robinson BG;Condon AF;Kielhold ML;Stormezand GN;Ma KY;Dufke C;Williams JT;Neve KA;Tijssen MAJ;Verbeek DS
- 通讯作者:Verbeek DS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIM Arthur NEVE其他文献
KIM Arthur NEVE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIM Arthur NEVE', 18)}}的其他基金
Dopamine D2 Receptor Mutations and Hyperkinetic Movement Disorders
多巴胺 D2 受体突变和多动性运动障碍
- 批准号:
10640977 - 财政年份:2022
- 资助金额:
$ 34.5万 - 项目类别:
Dopamine D2 Receptor Splice Variants and Autoreceptor Function
多巴胺 D2 受体剪接变体和自身受体功能
- 批准号:
9241697 - 财政年份:2016
- 资助金额:
$ 34.5万 - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8259083 - 财政年份:2010
- 资助金额:
$ 34.5万 - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8397575 - 财政年份:2010
- 资助金额:
$ 34.5万 - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8195874 - 财政年份:2010
- 资助金额:
$ 34.5万 - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
7931040 - 财政年份:2010
- 资助金额:
$ 34.5万 - 项目类别:
CHARACTERIZATION OF NOVEL G-ALPHA INTERACTING PROTEINS
新型 G-α 相互作用蛋白的表征
- 批准号:
6027297 - 财政年份:1999
- 资助金额:
$ 34.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 34.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 34.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 34.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)